PF-Atlas › Clinical Trials › NCT00909532
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
Ivacaftor · Phase 3
Registry ID
NCT00909532
Phase
Phase 3
Status
Completed
Drug / intervention
Ivacaftor
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2009-06
About this trial
Ivacaftor is evaluated in NCT00909532, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00909532 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.